neurology-2017-scientifictracks-abstracts

2 / 34

Volume 8, Issue 2 (Suppl) J Neurol Neurophysiol
ISSN: 2155-9562 JNN, an open access journal Neurology 2017
March 27-29, 2017
Page 34
Notes:
conferenceseries.com
March 27-29, 2017 Madrid, Spain
11th World Congress on
Neurology and Therapeutics
Neurofeedback: An alternative vision in the treatment of neurological and neuropsychiatric disorders
Electroencephalographic (EEG) biofeedback or often referred as Neurofeedback (NFB) was discovered about 40 years ago.
Over a long period, the technique remained unpopular, which is investigated by few enthusiasts. In the late 90s and in early
2000s, there started a new era of the Neurofeedback. The technological advances helped faster development and quicker testing
of new protocols and methods. During the last years, close to 200 publications are made every year about NFB and thousands
of clinicians are applying the technique in daily basis in their practices. One of the most investigated topics has been ADD/
ADHD and in 2012, American Academy of Pediatrics placed EEG biofeedback as a level-1 “Best Supported” intervention to
ADHD. The Institute of Social Research and Development of Uncommon Diseases together with NeuroVitalia is treating
patients with NFB in Clinical Hospital San Carlos. We apply the technique to wide variety of patients. We treat, for example,
tics, Tourette’s syndrome, and epilepsy, where NFB is known to provide help, but we have also started applying it to patients
with leucodystrophy, neuromuscular diseases and brain injuries. In the clinics of NeuroVitalia, we usually treat ADHD, autism,
migraine, anxiety and depression. We also have many peak performance clients.
Biography
Jyri Kuusela is the founder of NeuroVitalia and Ataman Science. He is also Neurofeedback lecturer of EEG Info-Europe and qEEG/ERP lecturer of HBImed.
Jyri Kuusela and Pilar Vecina
Clinical Hospital San Carlos, Spain
Jyri Kuusela et al., J Neurol Neurophysiol 2017, 8:2 (Suppl)